| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Oxford Biomedica announces Sanofi's intention to end agreement for haemophilia gene therapy work
StockMarketWire.com
|
Gene and cell therapy group Oxford Biomedica said that Sanofi's decision to terminate the collaboration and license agreement in the field of haemophilia gene therapy will have a 'negligible' impact on revenue.
The company announced that Sanofi has given notice to terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat haemophilia.
Oxford Biomedica said: 'The group expects that the impact on revenue will be negligible over the coming 24 month period.'
The agreement was originally signed with Bioverati, which was acquired by Sanofi in February 2018.
Story provided by StockMarketWire.com
|
|
|
|
|
|
